Brief: C4 Therapeutics Says CFT1946 Well-Tolerated At All Dose Levels No Dose-Limiting Toxicities
13/09/2024 17:00
Sept 13 (Reuters) - C4 Therapeutics Inc CCCC.O :
* C4 THERAPEUTICS PRESENTS MONOTHERAPY DATA DEMONSTRATING
PROOF OF
MECHANISM AND EARLY EVIDENCE OF PROOF OF CONCEPT FROM ONGOING
CFT1946 PHASE 1 TRIAL IN BRAF V600 MUTANT SOLID TUMORS AT THE
EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS 2024
* C4 THERAPEUTICS INC - CFT1946 WELL-TOLERATED AT ALL DOSE
LEVELS;
NO DOSE-LIMITING TOXICITIES
Source text for Eikon: ID:nGNX384Nfq
Further company coverage: CCCC.O
((Reuters.Briefs@thomsonreuters.com;))